• Computer Sciences Corp., of El Segundo, Calif., said DynPort Vaccine Co. LLC, of Frederick, Md., has entered a Phase II trial for its recombinant plague vaccine candidate, rF1V. The study will test different vaccine dosages and schedules in 400 healthy volunteers between the ages of 18 and 55. The clinical trial is under way and will continue into 2007 at eight locations across the U.S.
• Cougar Biotechnology Inc., of Los Angeles, enrolled the first patient in a Phase I trial of CB7630 (abiraterone acetate), its orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17, 20 lyase for advanced prostate cancer. The study will evaluate daily dosing of CB7630 in patients with chemotherapy-na ve hormone-refractory prostate cancer with a rising PSA despite hormonal therapy.
• Neoprobe Corp., of Dublin, Ohio, initiated a Phase II study of Lymphoseek, its lymphatic tissue-targeting agent to detect lymph nodes in breast and melanoma cancers during biopsy procedures. If safety and efficacy findings are confirmed, the product is expected to move into a pivotal trial.
• Serenex Inc., of Durham, N.C., started a Phase II trial with its lead product, SNX-1012, in patients with certain solid tumors who are treated with chemotherapy and develop oral mucositis. The study will compare multiple doses of SNX-1012 against a placebo control and is expected to be completed in early 2007.
ZymoGenetics Inc., of Seattle, said a Phase I trial is under way using interleukin-21 in combination with the monoclonal antibody Rituxan (rituximab). The trial is enrolling patients with advanced non- Hodgkin's lymphoma in a multi-site study in the U.S. Patients will be treated with Rituxan and IL-21 once weekly for four weeks. Responding patients will be offered the combination regimen for four additional weeks.